Nanoparticle-based theranostic platform for diagnosis and treatment of senescence-related pathologies

Polymeric nanoparticles targeting P-selectin effectively address the limitations of current senolytics by selectively eliminating senescent cells, improving tissue function, and enhancing anti-cancer therapy efficacy with reduced toxicity.

WO2024229271A1PCT designated stage expired Publication Date: 2024-11-07MEMORIAL SLOAN KETTERING CANCER CENT +2
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/027510
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-11-03
Filing Date
2024-05-02
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

Current small-molecule senolytics lack specificity and have dose-limiting toxicities, and there is a need for effective therapeutics against senescence-associated pathologies such as atherosclerosis, Alzheimer’s disease, and cancer, where senescent cells contribute to disease progression and resistance to anti-cancer therapies.

Method used

Polymeric nanoparticles with affinity to P-selectin, comprising a non-covalent assembly of sulfated polymers and senolytic or senomorphic drugs, are used to selectively target and eliminate senescent cells, reducing off-target toxicity and enhancing the efficacy of anti-cancer therapies.

Benefits of technology

The nanoparticles effectively target and reduce senescent cells in various tissues, improving tissue function, reducing fibrosis, and enhancing the effectiveness of anti-cancer therapies while minimizing toxicities associated with traditional senolytic drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024027510_07112024_PF_FP_ABST
    Figure US2024027510_07112024_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure provides polymeric nanoparticle compositions and methods of using the same to treat senescence-associated pathologies and improving tumor responses to anti-cancer therapies, such as immunotherapy (e.g., immune checkpoint blockade therapy), adoptive cell therapy, chemotherapy, or radiation therapy and the like. Also disclosed herein are methods of using the polymeric nanoparticle compositions of the present technology to improve tissue function after organ transplantation, hip replacement etc. In some embodiments, the polymeric nanoparticles described herein have an affinity to P-selectin and comprise a senolytic or senomorphic drug.
Need to check novelty before this filing date? Find Prior Art

Description

NANOPARTICLE-BASED THERANOSTIC PLATFORM FOR DIAGNOSIS AND TREATMENT OF SENESCENCE-RELATED PATHOLOGIESCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of and priority to U.S. Provisional Application No. 63 / 463,638, filed May 3, 2023, and U.S. Provisional Application No. 63 / 596,183, filed November 3, 2023, which are incorporated herein by reference in their entireties.TECHNICAL FIELD

[0002] The present technology relates generally to polymeric nanoparticle compositions having an affinity to P-selectin and comprising a senolytic or senomorphic drug, and methods of using the same to treat senescence-associated pathologies and / or improving tumor responsiveness to anti-cancer therapies. Also disclosed herein are methods of using the polymeric nanoparticle compositions of the present technology to improve tissue function after organ transplantation, hip replacement etc. Examples of senescence- associated pathologies include, but are not limited to atherosclerosis, Alzheimer’s disease, Parkinson’s disease, diabetic nephritis, diabetes, fibrotic diseases, metabolic dysfunction, stroke, chronic kidney disease, osteoarthritis, ischemic injury, sarcopenia, and organ decline after viral infection or cytotoxic cancer therapy.BACKGROUND

[0003] The following description of the background of the present technology is provided simply as an aid in understanding the present technology and is not admitted to describe or constitute prior art to the present technology.

[0004] The aberrant accumulation of senescent cells occurs in lung and liver fibrosis, atherosclerosis, diabetes, osteoarthritis and neurodegenerative disorders as well as malignant tumors (altogether >4,000,000 cases / year in the US). Genetic ablation of these senescent cells can ameliorate these pathologies in mice and, by reducing pro-tumorigenic inflammation, prevent cancer progression and metastasis. Current small-molecule “senolytics”, however, lack specificity and have dose-limiting toxicities. Additionally, strategies to direct use of these agents, or assess response are lacking.

[0005] Accordingly, there is an urgent need for effective therapeutics against these senescence-associated pathologies.SUMMARY OF THE PRESENT TECHNOLOGY

[0006] In one aspect, the present disclosure provides a method for treating a senescence- associated pathology in a subject in need thereof comprising administering to the subject an effective amount of a polymeric nanoparticle with affinity to P-selectin, wherein the nanoparticle comprises a non-covalent assembly of (a) a sulfated polymer species comprising free hydroxyl moi eties and free sulfate moi eties capable of targeting P-selectin, the sulfated polymer species comprising one or more of a sulfated polysaccharide, a protein, or a fucoidan; and (b) a senolytic or senomorphic drug; and optionally, a dye comprising a fluorophore, wherein the non-covalent assembly is a self-assembly of the sulfated polymer species around the senolytic or senomorphic drug; and wherein the subject exhibits an increased accumulation of senescent cells compared to a healthy control subject. Examples of senescence-associated pathologies include atherosclerosis, Alzheimer’s disease, Parkinson’s disease, diabetic nephritis, diabetes, fibrotic diseases (e.g., lung fibrosis, liver fibrosis), metabolic dysfunction, stroke, chronic kidney disease, osteoarthritis, ischemic injury, sarcopenia, and organ decline after viral infection or cytotoxic cancer therapy.

[0007] In one aspect, the present disclosure provides a method for enhancing the efficacy of an anti-cancer therapy in a subject in need thereof comprising administering to the subject an effective amount of a polymeric nanoparticle with affinity to P-selectin, wherein the nanoparticle comprises a non-covalent assembly of (a) a sulfated polymer species comprising free hydroxyl moi eties and free sulfate moieties capable of targeting P- selectin, the sulfated polymer species comprising one or more of a sulfated polysaccharide, a protein, or a fucoidan; and (b) a senolytic or senomorphic drug; and optionally, a dye comprising a fluorophore; wherein the non-covalent assembly is a self-assembly of the sulfated polymer species around the senolytic or senomorphic drug; and wherein the subject comprises a tumor microenvironment including senescent cells. The anti -cancer therapy may comprise immunotherapy (e.g., immune checkpoint blockade therapy), adoptive cell therapy, chemotherapy, radiation therapy, and the like. In some embodiments, the polymeric nanoparticle is configured to selectively target senescent cells in the tumor microenvironment. The adoptive cell therapy may comprise CAR T cell therapy or donor lymphocyte infusion. Additionally or alternatively, in some embodiments, the immunotherapy or adoptive cell therapy is administered intravenously, intratumorally, intraperitoneally, subcutaneously, intramuscularly, or intratumorally. Additionally or alternatively, in some embodiments, the efficacy of the anti -cancer therapy is improved byeliminating fibrosis caused by the anti-cancer therapy.

[0008] In another aspect, the present disclosure provides a method for preventing or mitigating metastasis in a subject in need thereof comprising administering to the subject an effective amount of a polymeric nanoparticle with affinity to P-selectin, wherein the nanoparticle comprises a non-covalent assembly of (a) a sulfated polymer species comprising free hydroxyl moi eties and free sulfate moi eties capable of targeting P-selectin, the sulfated polymer species comprising one or more of a sulfated polysaccharide, a protein, or a fucoidan; and (b) a senolytic or senomorphic drug; and optionally, a dye comprising a fluorophore; wherein the non-covalent assembly is a self-assembly of the sulfated polymer species around the senolytic or senomorphic drug; and wherein the subject exhibits an increased accumulation of senescent cells compared to a healthy control subject. In some embodiments, the subject is diagnosed with or suffers from cancer. In certain embodiments, the cancer is breast cancer, endometrial cancer, ovarian cancer, colon cancer, lung cancer, stomach cancer, prostate cancer, renal cancer, pancreatic cancer, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), or acute myeloid leukemia (AML). The cancer may be a relapsed or refractory cancer.

[0009] In yet another aspect, the present disclosure provides a method for improving tissue function or organ recovery in a subject in need thereof comprising administering to the subject an effective amount of a polymeric nanoparticle with affinity to P-selectin, wherein the nanoparticle comprises a non-covalent assembly of (a) a sulfated polymer species comprising free hydroxyl moieties and free sulfate moieties capable of targeting P- selectin, the sulfated polymer species comprising one or more of a sulfated polysaccharide, a protein, or a fucoidan; and (b) a senolytic or senomorphic drug; and optionally, a dye comprising a fluorophore; wherein the non-covalent assembly is a self-assembly of the sulfated polymer species around the senolytic or senomorphic drug; and wherein the subject has received surgery and exhibits an increased accumulation of senescent cells compared to a healthy control subject. In some embodiments, the subject is an organ or tissue transplant recipient or an arthroplasty recipient. In certain embodiments, the subject is a recipient of a skin graft, a blood vessel graft, a bone graft, a bone marrow graft or a limb transplant e.g., hands, arms and feet). Additionally or alternatively, in some embodiments, the organ or tissue transplant involves an organ or tissue selected from the group consisting of heart, kidney, liver, lung, pancreas, stomach, intestine, cornea, bone, tendon, skin, pancreas islets, heart valves, nerves, veins, bone marrow and stem cells. In certain embodiments, thearthroplasty comprises one or more of hip replacement, knee replacement, shoulder joint replacement, shoulder replacement, elbow replacement, and wrist joint replacement.

[0010] Additionally or alternatively, in some embodiments of methods disclosed herein, the senolytic or senomorphic drug is hydrophobic. In certain embodiments, the senolytic drug comprises one or more of navitoclax, fisetin, dasatinib, quercetin, luteolin, curcumin, curcumin analog EF24, A1331852, Al 155463, geldanamycin, tanespimycin, alvespimycin, piperlongumine, FOXO4-related peptide, Nutlin3a, ouabain, proscillaridin A, digoxin or cardiac glycosides. In some embodiments, the senomorphic drug comprises one or more of BET-inhibitor PROTAC dBET6, CDK9 inhibitors (e.g., AZD-4573, KB-0742, Alvocidib Hydrochloride, AT-7519, FIT-039, GFH-009, QHRD107, enitociclib, fadraciclib, flavopiridol, dinaciclib, seliciclib, SNS-032, RGB-286638, NVP-2 etc.), rapamycin, resveratrol, kaempferol, apigenin, EGCG, metformin, ruxolitinib, cortisol, corticosterone, loperamide, niguldipine, KU-60019, NBD peptide or Mmu-miR-2910-3p.

[0011] In any and all embodiments of the methods disclosed herein, the polymeric nanoparticle has an intensity-weighted average diameter as determined by dynamic light scattering of about 20 nm and about 200 nm and / or is negatively charged. Additionally or alternatively, in certain embodiments, the sulfated polymer species comprises a fucoidan and optionally, dextran sulfate.

[0012] In any of the preceding embodiments of the methods disclosed herein, the dye is a near infra-red dye. In some embodiments, the near infra-red dye is selected from the group consisting of IR783, IR-5, IR-26, IR-1048, IR-1061, CF®700, CF®750, CF®770, CF®790, CF®700, CF®800, CF®820, CF®850, and CF®870.

[0013] In any and all embodiments of the methods disclosed herein, the polymeric nanoparticle exhibits reduced off-target toxicity relative to the senolytic or senomorphic drug. The off-target toxicity may comprise one or more of leukopenia, neutropeni a, thrombocytopenia, dysgeusia, diarrhea, fatigue, nausea and anemia.BRIEF DESCRIPTION OF THE DRAWINGS

[0014] FIG. 1A: P-selectin [Selp] is upregulated in a model of p53-induced senescence. FIG. IB: P-selectin is expressed upon p53 restoration. FIG. 1C: P-selectin is upregulated and co-localize with senescent cells in a model of CCL4-induced liver fibrosis. FIG. ID: P-selectin co-localize with senescent cells in a murine model of Bleomycin-induced lung fibrosis.

[0015] FIG. 2A: Schematic of drug encapsulation in nanoparticles. FIGs. 2B-2D: Visualization of nanoparticles in vitro (FIG. 2B) and in vivo (FIGs. 2C-2D) in a p53- induced senescence model. FIG. 2E: Nanoparticles specifically target senescent cells in liver fibrosis in vivo.

[0016] FIGs. 3A-3B: Encapsulation of dBET6 in Fucoidan-specific nanoparticles significantly reduces toxicity. FIG. 3C: Nanoparticle delivery of dBET6 prevents from dysmegakaryopoiesis. FIG. 3D: Encapsulation of navitoclax in nanoparticles prevents from severe hematopoietic toxicities.

[0017] FIGs. 4A-4B: Nanoparticles loaded with navitoclax (FIG. 4A) or the PROTAC dBET6 (FIG. 4B) efficiently reduce liver fibrosis.

[0018] FIGs. 5A-5B: Nanoparticles loaded with navitoclax (FIG. 5A) or the PROTAC dBET6 (FIG. 5B) efficiently reduce lung fibrosis.

[0019] FIG. 6A: P-selectin expression is upregulated in human liver fibrosis and is associated with the degree of collagen deposition. FIG. 6B: P-selectin expression is upregulated in human lung fibrosis and is positively correlated with collagen deposition.

[0020] FIG. 7A: Nanoparticles specifically target senescent cells in liver fibrosis in vivo. FIG. 7B: Nanoparticles specifically target senescent cells in lung fibrosis in vivo.

[0021] FIG. 8A: Schematic of senescent cell pre-clearance with Fi-Navitoclax nanoparticles followed by tail vein injection of murine pancreatic cancer cells (PDAC) in bleomycin-induced fibrotic lungs. FIG. 8B: Fi-Navitoclax nanoparticles remodels the fibrotic microenvironment in lungs. FIG. 8C: Clearance of senescent cells with Fi- Navitoclax nanoparticles reduces metastatic seeding and metastasis progression of pancreatic cancer cells.

[0022] FIGs. 9A-9B: P-selectin co-localize with senescent cells in various aged tissues including heart, lung, liver, pancreas and kidney ([FIG. 9A] young organs, [FIG. 9B] aged organs).

[0023] FIG. 10A: P-selectin targeting nanoparticles enrich in old animals and can be imaged in vivo. FIG. 10B: Encapsulation of dBET6 in Fucoidan-specific nanoparticles significantly enrich in heart, lung, liver, kidney and pancreas.

[0024] FIG. 11: Nanoparticles loaded with navitoclax or the PROTAC dBET6 efficiently reduce fibrosis in aged hearts, lungs, livers, pancreas and kidneys.

[0025] FIG. 12A: Ultrasound guided quantification of liver blood flow velocity in the portal vein of the liver. FIG. 12B: Portal vein flow velocity significantly dropped in liver fibrosis. FIG. 12C: Nanoparticles loaded with navitoclax or the PROTAC dBET6 restores liver perfusion [increases portal vein flow velocity],

[0026] FIGs. 13A-13D: Nanoparticles loaded with navitoclax or the PROTAC dBET6 prevent from typical drug-related to toxicity (FIG. 13A leukopenia, FIG. 13B neutropenia, FIG. 13C anemia and FIG. 13D thrombocytopenia).

[0027] FIG. 14A: P-selectin+ Senescent cells accumulate in human lung fibrosis. FIG. 14B: P-selectin+ Senescent cells accumulate in human liver fibrosis.

[0028] FIG. 15A: Validation of P-selectin (Selp) knockdown in a model of p53-induced senescence. FIG. 15B: P-selectin knockdown decreases fucoidan nanoparticle uptake in senescent cells. FIG. 15C: P-selectin knockdown inhibits FiNav-induced (navitoclax encapsulated in fucoidan nanoparticle) cell death in senescent cells.

[0029] FIGs. 16A-16B: Fucal mRNA expression is upregulated in senescent cells. FIGs. 16C-16D: FUCA1 enzymatic activity is increased in senescent cells. FIG. 16E: FUCA1 enzymatic activity is increased upon liver fibrosis. FIG. 16F: FUCA1 enzymatic activity is increased upon lung fibrosis.

[0030] FIG. 17A: Validation of Fucal knockdown in a model of p53-induced senescence. FIG. 17B: Fucal knockdown decreases FUCA1 enzymatic activity in senescent cells. FIG. 17C: Fucal knockdown does not affect fucoidan nanoparticle uptake in senescent cells. FIG. 17D: Fucal knockdown delays FiNav-induced (navitoclax encapsulated in fucoidan nanoparticle) cell death in senescent cells.

[0031] FIG. 18: P -selectin knockdown and Fucal knockdown reduce Fi-dBET6- induced (dBET6, a BRD4 PROTAC, encapsulated in fucoidan nanoparticle) BRD4 degradation in senescent cells.

[0032] FIG. 19A: FiNav and FidBET6 treatment changes the SASP profile in fibrotic lungs. FIG. 19B: FiNav and FidBET6 treatment changes the SASP profile in fibrotic livers. FIG. 19C: 13 proteins are commonly downregulated between FiNav and FidBET6 treatment in both fibrotic lung and liver.

[0033] FIGs. 20A-20B: Immunostaining of monocytes / macrophages (CD68 / CD163), T cells (CD3), cytotoxic CD8 T cells (CDl lb), exhausted T cells (PD-1), and Granzyme B inhuman fibrotic lungs. FIGs. 20C-20E: High fibrotic burden correlates with an increase of macrophages, exhausted CD8 T cells and a decrease in effective CD8 T cells in human fibrotic lungs. FIG. 20F: FiNav and Fi-dBET6 treatment reduces macrophages and increases CD8 T cells in fibrotic lungs.DETAILED DESCRIPTION

[0034] It is to be appreciated that certain aspects, modes, embodiments, variations and features of the present methods are described below in various levels of detail in order to provide a substantial understanding of the present technology.

[0035] The present disclosure is not to be limited in terms of the particular embodiments described in this application, which are intended as single illustrations of individual aspects of the disclosure. All the various embodiments of the present disclosure will not be described herein. Many modifications and variations of the disclosure can be made without departing from its spirit and scope, as will be apparent to those skilled in the art.Functionally equivalent methods and apparatuses within the scope of the disclosure, in addition to those enumerated herein, will be apparent to those skilled in the art from the foregoing descriptions. Such modifications and variations are intended to fall within the scope of the appended claims. The present disclosure is to be limited only by the terms of the appended claims, along with the full scope of equivalents to which such claims are entitled.

[0036] It is to be understood that the present disclosure is not limited to particular uses, methods, reagents, compounds, compositions or biological systems, which can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.

[0037] In practicing the present methods, many conventional techniques in molecular biology, protein biochemistry, cell biology, microbiology and recombinant DNA are used. See, e.g., Sambrook and Russell eds. (2001) Molecular Cloning: A Laboratory Manual, 3rd edition; the series Ausubel et al. eds. (2007) Current Protocols in Molecular Biology, the series Methods in Enzymology (Academic Press, Inc., N.Y.); MacPherson et al. (1991) PCR 1: A Practical Approach (IRL Press at Oxford University Press); MacPherson et al. (1995) PCR 2: A Practical Approach,' Harlow and Lane eds. (1999) Antibodies, A Laboratory Manual,' Freshney (2005) Culture of Animal Cells: A Manual of Basic Technique, 5th edition; Gait ed. (1984) Oligonucleotide Synthesis,' U.S. Patent No. 4,683,195; Hames andHiggins eds. (1984) Nucleic Acid Hybridization,' Anderson (f 999) Nucleic Acid Hybridization,' Hames and Higgins eds. (1984) Transcription and Translation; Immobilized Cells and Enzymes (IRL Press (1986)); Perbal (1984) A Practical Guide to Molecular Cloning; Miller and Calos eds. (1987) Gene Transfer Vectors for Mammalian Cells (Cold Spring Harbor Laboratory); Makrides ed. (2003) Gene Transfer and Expression in Mammalian Cells; Mayer and Walker eds. (1987) Immunochemical Methods in Cell and Molecular Biology (Academic Press, London); and Herzenberg et al. eds (1996) Weir ’s Handbook of Experimental Immunology.

[0038] The Examples herein demonstrate that fluorescent nanoparticles targeting p- selectin — a protein upregulated on senescent cells and in the vasculature of damaged tissues — can selectively deliver distinct senescence-modulating drugs to senescent cells in vitro and in vivo. In both formulations, these therapies led to a marked improvement in liver and lung fibrosis, while dramatically reducing the toxicities observed by the naked senescence-modulating compounds. The present disclosure provides theranostic agents for enhancing the effectiveness and specificity of various senolytic and / or senomorphic drug formulations in the treatment of senescence-associated pathologies. As demonstrated here, fucodian nanoparticles bind P-selectin on endothelial cells but they unexpectedly pass through. Without wishing to be bound by theory, it is believed that the presence of fucosidase may enable release of the nanoparticles specifically in the senescent cells.

[0039] Accordingly, the P-selectin-targeting nanoparticles of the present technology are useful in methods for treating or ameliorating the effects of senescence-associated pathologies, and improving the responsiveness of cancer patients to anti-cancer therapies such as immunotherapy or CAR T cell therapy and / or preventing metastatic disease.Definitions

[0040] Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this disclosure belongs. The following references provide one of skill with a general definition of many of the terms used in the present disclosure. Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed. 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R. Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991). As used herein, the following terms have the meanings ascribed to them below, unless specifiedotherwise. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the disclosure.

[0041] As used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise.

[0042] As used herein, the term “about” or “approximately” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, z.e., the limitations of the measurement system. For example, “about” can mean within 3 or more than 3 standard deviations, per the practice in the art. Alternatively, “about” can mean a range of up to 20%, up to 10%, up to 5%, or up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, within 5 -fold, or within 2-fold, of a value.

[0043] As used herein, the term “administration” of an agent to a subject includes any route of introducing or delivering the agent to a subject to perform its intended function. Administration can be carried out by any suitable route, including, but not limited to, intravenously, intramuscularly, intraperitoneally, subcutaneously, and other suitable routes as described herein. Administration includes self-administration and the administration by another.

[0044] As used herein “adoptive cell therapeutic composition” refers to any composition comprising cells suitable for adoptive cell transfer. In exemplary embodiments, the adoptive cell therapeutic composition comprises a cell type selected from the group consisting of a tumor infiltrating lymphocyte (TIL), TCR (z.e., heterologous T- cell receptor), modified lymphocytes, and CAR (z.e., chimeric antigen receptor) modified lymphocytes. In another embodiment, the adoptive cell therapeutic composition comprises a cell type selected from the group consisting of T-cells, CD8+cells, CD4+cells, NK-cells, delta-gamma T-cells, regulatory T-cells and peripheral blood mononuclear cells. In another embodiment, TILs, T-cells, CD8+cells, CD4+cells, NK-cells, delta-gamma T-cells, regulatory T-cells or peripheral blood mononuclear cells form the adoptive cell therapeutic composition. In one embodiment, the adoptive cell therapeutic composition comprises T cells.

[0045] The term “amino acid” refers to naturally occurring and non-naturally occurring amino acids, as well as amino acid analogs and amino acid mimetics that function in amanner similar to the naturally occurring amino acids. Naturally encoded amino acids are the 20 common amino acids (alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine) and pyrolysine and selenocysteine. Amino acid analogs refer to agents that have the same basic chemical structure as a naturally occurring amino acid, z.e., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, such as, homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (such as, norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. In some embodiments, amino acids forming a polypeptide are in the D form. In some embodiments, the amino acids forming a polypeptide are in the L form. In some embodiments, a first plurality of amino acids forming a polypeptide are in the D form, and a second plurality of amino acids are in the L form.

[0046] Amino acids are referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, are referred to by their commonly accepted single-letter code.

[0047] As used herein, the term “analog” refers to a structurally related polypeptide or nucleic acid molecule having the function of a reference polypeptide or nucleic acid molecule.

[0048] As used herein, the term “antibody” means not only intact antibody molecules, but also fragments of antibody molecules that retain immunogen-binding ability. Such fragments are also well known in the art and are regularly employed both in vitro and in vivo. Accordingly, as used herein, the term “antibody” means not only intact immunoglobulin molecules but also the well-known active fragments F(ab')2, and Fab. F(ab')2, and Fab fragments that lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding of an intact antibody (Wahl et al., J. Nucl. Med. 24:316-325 (1983)). Antibodies may comprise whole native antibodies, monoclonal antibodies, human antibodies, humanized antibodies, camelised antibodies, multispecific antibodies, bispecific antibodies, chimeric antibodies, Fab, Fab', single chain V region fragments (scFv), single domain antibodies (e.g., nanobodies and single domain cam elid antibodies), VNAR fragments, Bi-specific T-cell engager (BiTE)antibodies, minibodies, disulfide-linked Fvs (sdFv), and anti-idiotypic (anti-Id) antibodies, intrabodies, fusion polypeptides, unconventional antibodies and antigen binding fragments of any of the above. In particular, antibodies include immunoglobulin molecules and immunologically active fragments of immunoglobulin molecules, z.e., molecules that contain an antigen binding site. Immunoglobulin molecules can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgGl, IgG2, IgG3, IgG4, IgAl, and IgA2), or subclass.

[0049] In certain embodiments, an antibody is a glycoprotein comprising at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds. Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant (CH) region. The heavy chain constant region is comprised of three domains, CHI, CH2, and CH3. Each light chain is comprised of a light chain variable region (abbreviated herein as VL) and a light chain constant CL region. The light chain constant region is comprised of one domain, CL. The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each VH and VL is composed of three CDRs and four FRs arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The constant regions of the antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Cl q) of the classical complement system. As used herein interchangeably, the terms “antigen binding portion”, “antigen binding fragment”, or “antigen binding region” of an antibody, refer to the region or portion of an antibody that binds to the antigen and which confers antigen specificity to the antibody; fragments of antigen binding proteins, for example antibodies, include one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g., an peptide / HLA complex). It has been shown that the antigen binding function of an antibody can be performed by fragments of a full-length antibody. Examples of antigen binding portions encompassed within the term “antibody fragments” of an antibody include a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CHI domains; a F(ab)2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; a Fd fragment consisting of the VH and CHI domains; a Fv fragmentconsisting of the VL and VH domains of a single arm of an antibody; a dAb fragment (Ward et al., Nature 341 : 544-546 (1989)), which consists of a VH domain; and an isolated complementarity determining region (CDR). An “isolated antibody” or “isolated antigen binding protein” is one which has been identified and separated and / or recovered from a component of its natural environment. “Synthetic antibodies” or “recombinant antibodies” are generally generated using recombinant technology or using peptide synthetic techniques known to those of skill in the art.

[0050] Antibodies and antibody fragments can be wholly or partially derived from mammals (e.g., humans, non-human primates, goats, guinea pigs, hamsters, horses, mice, rats, rabbits and sheep) or non-mammalian antibody producing animals (e.g., chickens, ducks, geese, snakes, and urodele amphibians). The antibodies and antibody fragments can be produced in animals or produced outside of animals, such as from yeast or phage (e.g., as a single antibody or antibody fragment or as part of an antibody library).

[0051] Furthermore, although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules. These are known as single chain Fv (scFv); see e.g., Bird et al., Science 242:423-426 (1988); and Huston et al., Proc. Natl. Acad. Sci. 85 : 5879-5883 (1988). These antibody fragments are obtained using conventional techniques known to those of ordinary skill in the art, and the fragments are screened for utility in the same manner as are intact antibodies.

[0052] As used herein, an “antigen” refers to a molecule to which an antibody can selectively bind. The target antigen may be a protein (e.g., an antigenic peptide), carbohydrate, nucleic acid, lipid, hapten, or other naturally occurring or synthetic compound. An antigen may also be administered to an animal subject to generate an immune response in the subject.

[0053] By “binding affinity” is meant the strength of the total noncovalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Without wishing to be bound by theory, affinity depends on the closeness of stereochemical fit between antibody combining sites and antigen determinants, on the size of the area of contact between them, and on the distribution of charged and hydrophobic groups. Affinity also includes the term “avidity,” which refers to the strength of theantigen-antibody bond after formation of reversible complexes (e.g., either monovalent or multivalent). Methods for calculating the affinity of an antibody for an antigen are known in the art, comprising use of binding experiments to calculate affinity. The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (Ka). A low-affinity complex contains an antibody that generally tends to dissociate readily from the antigen, whereas a high-affinity complex contains an antibody that generally tends to remain bound to the antigen for a longer duration. Antibody activity in functional assays (e.g., flow cytometry assay) is also reflective of antibody affinity. Antibodies and affinities can be phenotypically characterized and compared using functional assays (e.g., flow cytometry assay).

[0054] As used herein, “CDRs” are defined as the complementarity determining region amino acid sequences of an antibody which are the hypervariable regions of immunoglobulin heavy and light chains. See, e.g., Kabat et al., Sequences of Proteins of Immunological Interest, 4th U. S. Department of Health and Human Services, National Institutes of Health (1987). Generally, antibodies comprise three heavy chain and three light chain CDRs or CDR regions in the variable region. CDRs provide the majority of contact residues for the binding of the antibody to the antigen or epitope. In certain embodiments, the CDRs regions are delineated using the Kabat system (Kabat, E. A., et al. Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242(1991)).

[0055] As used herein, the term “chimeric co-stimulatory receptor” or “CCR” refers to a chimeric receptor that binds to an antigen and provides co-stimulatory signals, but does not provide a T-cell activation signal.

[0056] As used herein, a “control” is an alternative sample used in an experiment for comparison purpose. A control can be “positive” or “negative.” For example, where the purpose of the experiment is to determine a correlation of the efficacy of a therapeutic agent for the treatment for a particular type of disease, a positive control (a composition known to exhibit the desired therapeutic effect) and a negative control (a subject or a sample that does not receive the therapy or receives a placebo) are typically employed.

[0057] As used herein, the term, “co-stimulatory signaling domain,” or “co-stimulatory domain”, refers to the portion of the CAR comprising the intracellular domain of a co- stimulatory molecule. Co-stimulatory molecules are cell surface molecules other thanantigen receptors or Fc receptors that provide a second signal required for efficient activation and function of T lymphocytes upon binding to antigen. Examples of such costimulatory molecules include CD27, CD28, 4-1BB (CD137), 0X40 (CD134), CD30, CD40, PD-1, ICOS (CD278), LFA-1, CD2, CD7, LIGHT, NKD2C, B7-H2 and a ligand that specifically binds CD83. Accordingly, while the present disclosure provides exemplary costimulatory domains derived from CD28 and 4- IBB, other costimulatory domains are contemplated for use with the CARs described herein. The inclusion of one or more costimulatory signaling domains can enhance the efficacy and expansion of T cells expressing CAR receptors. The intracellular signaling and co-stimulatory signaling domains can be linked in any order in tandem to the carboxyl terminus of the transmembrane domain.

[0058] As used herein, the term “disease” refers to any condition or disorder that damages or interferes with the normal function of a cell, tissue, or organ.

[0059] As used herein, the term “effective amount” or “therapeutically effective amount” refers to a quantity of an agent sufficient to achieve a beneficial or desired clinical result upon treatment. In the context of therapeutic applications, the amount of a therapeutic agent administered to the subject can depend on the type and severity of the disease or condition and on the characteristics of the individual, such as general health, age, sex, body weight, effective concentration of the therapeutic agent administered, and tolerance to drugs. It can also depend on the degree, severity, and type of disease. The skilled artisan will be able to determine appropriate dosages depending on these and other factors. An effective amount can be administered to a subject in one or more doses. In terms of treatment, an effective amount is an amount that is sufficient to palliate, ameliorate, stabilize, reverse or slow the progression of the disease, or otherwise reduce the pathological consequences of the disease. The effective amount is generally determined by the physician on a case-by-case basis and is within the skill of one in the art.

[0060] As used herein, the term “expression” refers to the process by which polynucleotides are transcribed into mRNA and / or the process by which the transcribed mRNA is subsequently being translated into peptides, polypeptides, or proteins. If the polynucleotide is derived from genomic DNA, expression can include splicing of the mRNA in a eukaryotic cell. The expression level of a gene can be determined by measuring the amount of mRNA or protein in a cell or tissue sample. In one aspect, the expression level of a gene from one sample can be directly compared to the expression level of that gene from a control or reference sample. In another aspect, the expression level of a genefrom one sample can be directly compared to the expression level of that gene from the same sample following administration of the compositions disclosed herein. The term “expression” also refers to one or more of the following events: (1) production of an RNA template from a DNA sequence (e.g., by transcription) within a cell; (2) processing of an RNA transcript (e.g., by splicing, editing, 5’ cap formation, and / or 3’ end formation) within a cell; (3) translation of an RNA sequence into a polypeptide or protein within a cell; (4) post-translational modification of a polypeptide or protein within a cell; (5) presentation of a polypeptide or protein on the cell surface; and (6) secretion or presentation or release of a polypeptide or protein from a cell. The level of expression of a polypeptide can be assessed using any method known in art, including, for example, methods of determining the amount of the polypeptide produced from the host cell. Such methods can include, but are not limited to, quantitation of the polypeptide in the cell lysate by ELISA, Coomassie blue staining following gel electrophoresis, Lowry protein assay and Bradford protein assay.

[0061] As used herein, “F(ab)” refers to a fragment of an antibody structure that binds to an antigen but is monovalent and does not have a Fc portion, for example, an antibody digested by the enzyme papain yields two F(ab) fragments and an Fc fragment (e.g., a heavy (H) chain constant region; Fc region that does not bind to an antigen).

[0062] As used herein, “F(ab')2” refers to an antibody fragment generated by pepsin digestion of whole IgG antibodies, wherein this fragment has two antigen binding (ab1) (bivalent) regions, wherein each (ab1) region comprises two separate amino acid chains, a part of a H chain and a light (L) chain linked by an S-S bond for binding an antigen and where the remaining H chain portions are linked together. A “F(ab')2” fragment can be split into two individual Fab' fragments.

[0063] As used herein, the term “heterologous nucleic acid molecule or polypeptide” refers to a nucleic acid molecule (e.g., a cDNA, DNA or RNA molecule) or polypeptide that is not normally present in a cell or sample obtained from a cell. This nucleic acid may be from another organism, or it may be, for example, an mRNA molecule that is not normally expressed in a cell or sample.

[0064] As used herein, the term “immune cell” refers to any cell that plays a role in the immune response of a subject. Immune cells are of hematopoietic origin, and include lymphocytes, such as B cells and T cells; natural killer cells; myeloid cells, such as monocytes, macrophages, dendritic cells, eosinophils, neutrophils, mast cells, basophils, andgranulocytes. As used herein, the term “engineered immune cell” refers to an immune cell that is genetically modified. As used herein, the term “native immune cell” refers to an immune cell that naturally occurs in the immune system.

[0065] As used herein, the term “ligand” refers to a molecule that binds to a receptor. In particular, the ligand binds a receptor on another cell, allowing for cell-to-cell recognition and / or interaction.

[0066] The term “linker” refers to synthetic sequences (e.g., amino acid sequences) that connect or link two sequences, e.g., that link two polypeptide domains. In some embodiments, the linker contains 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid residues.

[0067] The term “lymphocyte” refers to all immature, mature, undifferentiated, and differentiated white blood cell populations that are derived from lymphoid progenitors including tissue specific and specialized varieties, and encompasses, by way of non-limiting example, B cells, T cells, NKT cells, and NK cells. In some embodiments, lymphocytes include all B cell lineages including pre-B cells, progenitor B cells, early pro-B cells, late pro-B cells, large pre-B cells, small pre-B cells, immature B cells, mature B cells, plasma B cells, memory B cells, B-l cells, B-2 cells, and anergic AN1 / T3 cell populations.

[0068] The terms “polypeptide,” “peptide,” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to naturally occurring amino acid polymers as well as amino acid polymers in which one or more amino acid residues are a non -naturally occurring amino acid, e.g., an amino acid analog. The terms encompass amino acid chains of any length, including full length proteins, wherein the amino acid residues are linked by covalent peptide bonds.

[0069] As used herein, the term “sample” refers to clinical samples obtained from a subject. In certain embodiments, a sample is obtained from a biological source (z.e., a "biological sample"), such as tissue, bodily fluid, or microorganisms collected from a subject. Sample sources include, but are not limited to, mucus, sputum, bronchial alveolar lavage (BAL), bronchial wash (BW), whole blood, bodily fluids, cerebrospinal fluid (CSF), urine, plasma, serum, or tissue.

[0070] As used herein, the term “separate” therapeutic use refers to an administration of at least two active ingredients at the same time or at substantially the same time by different routes.

[0071] As used herein, the term “sequential” therapeutic use refers to administration ofat least two active ingredients at different times, the administration route being identical or different. More particularly, sequential use refers to the whole administration of one of the active ingredients before administration of the other or others commences. It is thus possible to administer one of the active ingredients over several minutes, hours, or days before administering the other active ingredient or ingredients. There is no simultaneous treatment in this case.

[0072] As used herein, the term “simultaneous” therapeutic use refers to the administration of at least two active ingredients by the same route and at the same time or at substantially the same time.

[0073] As used herein, the term “single-chain variable fragment” or “scFv” is a fusion protein of the variable regions of the heavy (VH) and light chains (VL) of an immunoglobulin (e.g, mouse or human) covalently linked to form a VH: :VL heterodimer. The heavy (VH) and light chains (VL) are either joined directly or joined by a peptide- encoding linker (e.g, about 10, 15, 20, 25 amino acids), which connects the N-terminus of the VH with the C-terminus of the VL, or the C-terminus of the VH with the N-terminus of the VL. The linker is usually rich in glycine for flexibility, as well as serine or threonine for solubility. The linker can link the heavy chain variable region and the light chain variable region of the extracellular antigen binding domain.

[0074] Despite removal of the constant regions and the introduction of a linker, scFv proteins retain the specificity of the original immunoglobulin. Single chain Fv polypeptide antibodies can be expressed from a nucleic acid comprising VH- and Vr-encoding sequences as described by Huston, et al. (Proc. Nat. Acad. Set. USA, 85:5879-5883 (1988)). See, also, U.S. Patent Nos. 5,091,513, 5,132,405 and 4,956,778; and U.S. Patent Publication Nos. 20050196754 and 20050196754. Antagonistic scFvs having inhibitory activity have been described (see, e.g. , Zhao et al. , Hybridoma (Larchmt) 27(6):455-51 (2008); Peter et al. , J Cachexia Sarcopenia Muscle (2012); Shieh et al., J Imunol 183(4):2277-85 (2009);Giomarelli etal., Thromb Haemost 97(6):955-63 (2007); Fife eta., J Clin Invs 116(8):2252- 61 (2006); Brocks et al., Immunotechnology 3(3): 173-84 (1997); Moosmayer et al., Ther Immunol 2(10):31- 40 (1995). Agonistic scFvs having stimulatory activity have been described (see, e.g., Peter et al., J Biol Chem 25278(38):36740-7 (2003); Xie et al., Nat Biotech 15(8):768-71 (1997); Ledbetter et al., Crit Rev Immunol 17(5-6):427-55 (1997); Ho et al., Bio Chim Biophys Acta 1638(3):257-66 (2003)).

[0075] As used herein, the term “specifically binds” or “specifically binds to” or “specifically target” refers to a molecule (e.g., a polypeptide or fragment thereof) that recognizes and binds a molecule of interest (e.g., an antigen), but which does not substantially recognize and bind other molecules. The terms “specific binding,” “specifically binds to,” or is “specific for” a particular molecule (e.g., an antigen), as used herein, can be exhibited, for example, by a molecule having a Ka for the molecule to which it binds to of about 10"4M, 10"5M, 1(T6M, 10"7M, 10"8M, 1(T9M, 10l0M, 10 " M, or 10l 2M.

[0076] As used herein, the terms “subject,” “individual,” or “patient” are used interchangeably and refer to an individual organism, a vertebrate, or a mammal and may include humans, non-human primates, rodents, and the like (e.g., which is to be the recipient of a particular treatment, or from whom cells are harvested). In certain embodiments, the individual, patient or subject is a human.

[0077] As used herein, the term “T-cell” includes naive T cells, CD4+T cells, CD8+T cells, memory T cells, activated T cells, anergic T cells, tolerant T cells, chimeric B cells, and antigen-specific T cells.

[0078] “Treating” or “treatment” as used herein covers the treatment of a disease or disorder described herein, in a subject, such as a human, and includes: (i) inhibiting a disease or disorder, z.e., arresting its development; (ii) relieving a disease or disorder, z.e., causing regression of the disorder; (iii) slowing progression of the disorder; and / or (iv) inhibiting, relieving, or slowing progression of one or more symptoms of the disease or disorder. Therapeutic effects of treatment include, without limitation, inhibiting recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastases, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis. By “treating a pathology” is meant that the symptoms associated with the pathology are, e.g., alleviated, reduced, cured, or placed in a state of remission.

[0079] It is also to be appreciated that the various modes of treatment of diseases as described herein are intended to mean “substantial,” which includes total but also less than total treatment, and wherein some biologically or medically relevant result is achieved. The treatment may be a continuous prolonged treatment for a chronic disease or a single, or few time administrations for the treatment of an acute condition.Polymeric Nanoparticles of the Present Technology

[0080] The present disclosure provides a polymeric nanoparticle with affinity to P- selectin, the nanoparticle comprising (a) a non-covalent assembly of a sulfated polymer species comprising free hydroxyl moieties and free sulfate moieties capable of targeting P- selectin, the sulfated polymer species comprising one or more of a sulfated polysaccharide, a protein, or a fucoidan; and (b) a senolytic or senomorphic drug; and optionally, a dye comprising a fluorophore, wherein the non-covalent assembly is a self-assembly of the sulfated polymer species around the senolytic or senomorphic drug. In certain embodiments, the sulfated polymer species comprises a fucoidan and optionally, dextran sulfate. The fucoidan may be a sulfated polysaccharide comprising sulfated ester moieties of fucose. In certain embodiments, the nanoparticle has a core comprising albumin and a surface comprising fucoidan. In certain embodiments, the nanoparticle comprises polyethylene glycol (PEG), wherein the senolytic or senomorphic drug is conjugated to the polyethylene glycol via hydrozone linkages. In certain embodiments, the senolytic or senomorphic drug is not chemically conjugated to the sulfated polymer species, but is electrostatically bound to the sulfated polymer species.

[0081] Additionally or alternatively, in some embodiments, the senolytic or senomorphic drug is hydrophobic. In certain embodiments, the senolytic drug comprises one or more of navitoclax, fisetin, dasatinib, quercetin, luteolin, curcumin, curcumin analog EF24, A1331852, Al 155463, geldanamycin, tanespimycin, alvespimycin, piperlongumine, FOXO4-related peptide, Nutlin3a, ouabain, proscillaridin A, digoxin or cardiac glycosides. In some embodiments, the senomorphic drug comprises one or more of BET-inhibitor PROTAC dBET6, CDK9 inhibitors (e.g., AZD-4573, KB-0742, Alvocidib Hydrochloride, AT-7519, FIT-039, GFH-009, QHRD107, enitociclib, fadraciclib, flavopiridol, dinaciclib, seliciclib, SNS-032, RGB-286638, NVP-2 etc.), rapamycin, resveratrol, kaempferol, apigenin, EGCG, metformin, ruxolitinib, cortisol, corticosterone, loperamide, niguldipine, KU-60019, NBD peptide or Mmu-miR-2910-3p.

[0082] In some embodiments, the nanoparticle has an intensity-weighted average diameter of about 20 nm and about 200 nm, about 100 nm to about 200 nm or about 150 nm to about 170 nm as determined by dynamic light scattering. In certain embodiments, the nanoparticle has an intensity-weighted average diameter of about 20 nm, about 25 nm, about 30 nm, about 35 nm, about 40 nm, about 45 nm, about 50 nm, about 55 nm, about 60 nm, about 65 nm, about 70 nm, about 75 nm, about 80 nm, about 85 nm, about 90 nm, about95 nm, about 100 nm, about 105 nm, about 110 nm, about 115 nm, about 120 nm, about 125 nm, about 130 nm, about 135 nm, about 140 nm, about 145 nm, about 150 nm, about 155 nm, about 160 nm, about 165 nm, about 170 nm, about 175 nm, about 180 nm, about 185 nm, about 190 nm, about 195 nm, or about 200 nm, as determined by dynamic light scattering. Additionally or alternatively, in certain embodiments, the nanoparticle is negatively charged.

[0083] In any of the preceding embodiments, the dye is a near infra-red dye. Examples of near infra-red dyes include, but are not limited to IR783, IR-5, IR-26, IR-1048, IR-1061, CF®700, CF®750, CF®770, CF®790, CF®700, CF®800, CF®820, CF®850, and CF®870. In certain embodiments, the near infra-red dye is 2-[2-[2-chloro-3-[2-[l,3-dihydro-3,3- dimethyl-l-(4-sulfobutyl)-2H-indol-2-ylidene]ethylidene]-l-cyclohexen-l-yl]ethenyl]-3,3- dimethyl-l-(4-sulfobutyl)-3H-indolium sodium salt (IR783).

[0084] In some embodiments, the polymeric nanoparticles described herein can be manufactured by contacting a senolytic or senomorphic drug with a sulfated polymer species comprising free hydroxyl moieties and free sulfate moieties capable of targeting P- selectin, to form a mixture; and agitating the mixture to form nanoparticles. The sulfated polymer species may comprise one or more of a sulfated polysaccharide, a protein, or a fucoidan. In some embodiments, agitating the mixture comprises sonicating the mixture. In certain embodiments, the senolytic or senomorphic drug and the sulfated polymer species are precipitated together via nano-precipitation.Therapeutic Uses of the Nanoparticles of the Present Technology

[0085] In one aspect, the present disclosure provides a method for treating a senescence- associated pathology in a subject in need thereof comprising administering to the subject an effective amount of any and all embodiments of the P-selectin targeting polymeric nanoparticles described herein, wherein the subject exhibits an increased accumulation of senescent cells compared to a healthy control subject. Examples of senescence-associated pathologies include, but are not limited to, atherosclerosis, Alzheimer’s disease, Parkinson’s disease, diabetic nephritis, diabetes, fibrotic diseases (e.g., lung fibrosis, liver fibrosis), metabolic dysfunction, stroke, chronic kidney disease, osteoarthritis, ischemic injury, sarcopenia, and organ decline after viral infection or cytotoxic cancer therapy. The liver fibrosis may be caused by viral infection, alcoholic steatohepatitis, or nonalcoholic steatohepatitis.

[0086] In one aspect, the present disclosure provides a method for enhancing the efficacy of an anti-cancer therapy in a subject in need thereof comprising administering to the subject an effective amount of any and all embodiments of the P-selectin targeting polymeric nanoparticles described herein, wherein the subject comprises a tumor microenvironment including senescent cells. In some embodiments, the P-selectin targeting polymeric nanoparticles are configured to selectively target senescent cells in the tumor microenvironment. Additionally or alternatively, in some embodiments, the efficacy of the anti-cancer therapy is improved by eliminating fibrosis caused by the anti -cancer therapy. The anti-cancer therapy may comprise immunotherapy (e.g., immune checkpoint blockade therapy), adoptive cell therapy, chemotherapy, radiation therapy, and the like. In some embodiments, the adoptive cell therapy comprises CAR T cell therapy or donor lymphocyte infusion. The immunotherapy may comprise one or more of tumor specific monoclonal antibodies, immune checkpoint inhibitors and cytokines. In some embodiments, the cytokine is selected from the group consisting of interferon a, interferon P, interferon y, complement C5a, IL-2, TNF alpha, CD40L, IL12, IL-23, IL15, IL17, CCL1, CCL11, CCL12, CCL13, CCL14-1, CCL14-2, CCL14-3, CCL15-1, CCL15-2, CCL16, CCL17, CCL18, CCL19, CCL19, CCL2, CCL20, CCL21, CCL22, CCL23-1, CCL23-2, CCL24, CCL25-1, CCL25-2, CCL26, CCL27, CCL28, CCL3, CCL3L1, CCL4, CCL4L1, CCL5, CCL6, CCL7, CCL8, CCL9, CCR10, CCR2, CCR5, CCR6, CCR7, CCR8, CCRL1, CCRL2, CX3CL1, CX3CR, CXCL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL16, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL9, CXCR1, CXCR2, CXCR4, CXCR5, CXCR6, CXCR7 and XCL2.

[0087] In yet further embodiments, the immune checkpoint inhibitor comprises, or consists essentially of, or yet further consists of an antibody or an equivalent thereof recognizing and binding to an immune checkpoint protein, such as an antibody or an equivalent thereof recognizing and binding to CTLA4 (for example, Yervoy (ipilimumab), CP-675,206 (tremelimumab), AK104 (cadonilimab), or AGEN1884 (zalifrelimab)), or an antibody or an equivalent thereof recognizing and binding to PD-1 (for example, Keytruda (pembrolizumab), Opdivo (nivolumab), Libtayo (cemiplimab), Tyvyt (sintilimab), BGB- A317 (tislelizumab), JS001 (toripalimab), SHR1210 (camrelizumab), GB226 (geptanolimab), JS001 (toripalimab), AB122 (zimberelimab), AK105 (penpulimab), HLX10 (serplulimab), BCD-100 (prolgolimab), AGEN2034 (balstilimab), MGA012 (retifanlimab), AK104 (cadonilimab), HX008 (pucotenlimab), PF-06801591 (sasanlimab), JNJ-63723283 (cetrelimab), MGD013 (tebotelimab), CT-011 (pidilizumab), or Jemperli (dostarlimab)), oran antibody or an equivalent thereof recognizing and binding to PD-L1 (for example, Tecentriq (atezolizumab), Imfinzi (durvalumab), Bavencio (avelumab), CS1001 (sugemalimab), or KN035 (envafolimab)).

[0088] Examples of chemotherapeutic agents include but are not limited to, abraxane, capecitabine, erlotinib, fluorouracil (5-FU), gemcitabine, irinotecan, leucovorin, nab- paclitaxel, cisplatin, irinotecan, docetaxel, oxaliplatin, tipifarnib, everolimus, sunitinib, dovitinib, ruxolitinib, pegylated-hyaluronidase, pemetrexed, folinic acid, paclitaxel, MK2206, GDC-0449, IPI-926, gamma secretase / RO4929097, M402, LY293111 and cytotoxic antibiotics such as bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, plicamycin, mitomycin and mitoxantrone.

[0089] In certain embodiments of the methods disclosed herein, the immunotherapy or adoptive cell therapy is administered intravenously, intratum orally, intraperitoneally, subcutaneously, intramuscularly, or intratum orally.

[0090] In some embodiments, the P-selectin targeting polymeric nanoparticles and the immunotherapy or adoptive cell therapy are administered at different times. For example, in some embodiments, the P-selectin targeting polymeric nanoparticles are administered and then the immunotherapy or adoptive cell therapy is administered. In some embodiments, the immunotherapy or adoptive cell therapy is administered 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 18 hours, 24 hours, 30 hours, 26 hours, 48 hours or more than 48 hours after the administration of the P- selectin targeting polymeric nanoparticles of the present technology.

[0091] In another aspect, the present disclosure provides a method for preventing or mitigating metastasis in a subject in need thereof comprising administering to the subject an effective amount of any and all embodiments of the P-selectin targeting polymeric nanoparticles described herein, wherein the subject exhibits an increased accumulation of senescent cells compared to a healthy control subject. In any of the preceding embodiments, the subject is diagnosed with or suffers from cancer. The cancer may be breast cancer, endometrial cancer, ovarian cancer, colon cancer, lung cancer, stomach cancer, prostate cancer, renal cancer, pancreatic cancer, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and metastases thereof. In some embodiments, the cancer is a relapsed or refractory cancer. In some embodiments, the cancer is resistant to one or more anti -cancer therapies, e.g., one or more chemotherapeutic drugs.

[0092] In yet another aspect, the present disclosure provides a method for improvingtissue function or organ recovery in a subject in need thereof comprising administering to the subject an effective amount of a polymeric nanoparticle with affinity to P-selectin, wherein the nanoparticle comprises a non-covalent assembly of (a) a sulfated polymer species comprising free hydroxyl moieties and free sulfate moieties capable of targeting P- selectin, the sulfated polymer species comprising one or more of a sulfated polysaccharide, a protein, or a fucoidan; and (b) a senolytic or senomorphic drug; and optionally, a dye comprising a fluorophore; wherein the non-covalent assembly is a self-assembly of the sulfated polymer species around the senolytic or senomorphic drug; and wherein the subject has received surgery and exhibits an increased accumulation of senescent cells compared to a healthy control subject. In some embodiments, the subject is an organ or tissue transplant recipient or an arthroplasty recipient. In certain embodiments, the subject is a recipient of a skin graft, a blood vessel graft, a bone graft, a bone marrow graft or a limb transplant (e.g., hands, arms and feet). Additionally or alternatively, in some embodiments, the organ or tissue transplant involves an organ or tissue selected from the group consisting of heart, kidney, liver, lung, pancreas, stomach, intestine, cornea, bone, tendon, skin, pancreas islets, heart valves, nerves, veins, bone marrow and stem cells. In certain embodiments, the arthroplasty comprises one or more of hip replacement, knee replacement, shoulder joint replacement, shoulder replacement, elbow replacement, and wrist joint replacement.

[0093] Also disclosed herein are methods for monitoring / tracking senescent cells in a subject comprising administering to the subject an effective amount of any and all embodiments of the P-selectin targeting polymeric nanoparticles described herein, and detecting signals emitted by the dye comprising the fluorophore, wherein the subject exhibits an increased accumulation of senescent cells compared to a healthy control subject and wherein the P-selectin targeting polymeric nanoparticles are configured to selectively target senescent cells in the subject.

[0094] The P-selectin targeting polymeric nanoparticles of the presently disclosed subject matter can be administered by any methods known in the art, including, but not limited to, intranasal administration, pleural administration, intravenous administration, subcutaneous administration, intranodal administration, intratumoral administration, intrathecal administration, intrapleural administration, intraperitoneal administration, intramuscular administration, iontophoretic administration, and direct administration to the thymus. In any and all embodiments of the methods disclosed herein, the subject is human.

[0095] The subjects can have an advanced form of disease, in which case the treatment objective can include mitigation or reversal of disease progression, and / or amelioration ofside effects. The subjects can have a history of the condition, for which they have already been treated, in which case the therapeutic objective will typically include a decrease or delay in the risk of recurrence.

[0096] In any and all embodiments of the methods disclosed herein, the polymeric nanoparticle exhibits reduced off-target toxicity (such as leukopenia, neutropenia, thrombocytopenia, dysgeusia, diarrhea, fatigue, nausea and anemia) relative to the senolytic or senomorphic drug.Combination Therapy

[0097] Also provided are methods for treating a senescence-associated pathology in a subject in need thereof comprising administering to the subject an effective amount of any of the P-selectin targeting polymeric nanoparticles provided herein and an additional therapy. Without wishing to be bound by theory, it is believed that the induction of senescence in the tumor cells would further increase the uptake of nanoparticles based on the mechanisms herein. In certain embodiments, the additional therapy comprises P- selectin-targeting polymeric nanoparticles comprising an anti-cancer drug such as those described in US Patent No. 10,478,506, which is incorporated herein by reference in its entirety.

[0098] Methods for treating lung fibrosis may further comprise sequentially, separately, or simultaneously administering to the subject at least one additional therapy selected from among pirfenidone, nintedanib, oxygen therapy, corticosteroids (e.g., prednisone), mycophenolate mofetil / mycophenolic acid, and azathioprine.

[0099] Methods for treating atherosclerosis may further comprise sequentially, separately, or simultaneously administering to the subject at least one additional therapy selected from among statins (e.g., Atorvastatin, Fluvastatin, Lovastatin, Pitavastatin, Pravastatin, Rosuvastatin calcium, Simvastatin), fibrates (e.g., Gemfibrozil, Fenofibrate), niacin, ezetimibe, bile acid sequestrants (e.g., cholestyramine, colestipol, colesevelam), proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors, anti-platelet medications (e.g., aspirin, Clopidogrel, Ticagrelor, warfarin, prasugral), beta blockers, Angiotensinconverting enzyme (ACE) inhibitors, calcium channel blockers, and diuretics.

[0100] Methods for treating Alzheimer’s disease may further comprise sequentially, separately, or simultaneously administering to the subject at least one additional therapy selected from among donepezil, galantamine, memantine, rivastigmine, memantineextended-release and donepezil (Namzaric), aducanumab, solanezumab, insulin, verubecestat, AADvacl, CSP-1103, and intepirdine.

[0101] Methods for treating diabetes may further comprise sequentially, separately, or simultaneously administering to the subject at least one additional therapy selected from among insulin, metformin, amylin analogs, glucagon, sulfonylureas (e.g.,glimepiride, glipizide, glyburide, chlorpropamide, tolazamide, tolbutamide), meglitinides (e.g., nateglinide, repaglinide), thiazolidinediones (e.g., pioglitazone, rosiglitazone), alphaglucosidase inhibitors (e.g., acarbose, miglitol), dipeptidyl peptidase (DPP-4) inhibitors (e.g., alogliptin, linagliptin, sitagliptin, saxagliptin), sodium-glucose co-transporter 2 (SGLT2) inhibitors (e.g., canagliflozin, dapagliflozin, empagliflozin, ertugliflozin), and incretin mimetics (e.g., exenatide, liraglutide, dulaglutide, lixisenatide, semaglutide).

[0102] Methods for treating osteoarthritis may further comprise sequentially, separately, or simultaneously administering to the subject at least one additional therapy selected from among analgesics (e.g., acetaminophen, tramadol, oxycodone, hydrocodone), nonsteroidal anti-inflammatory drugs (e.g., aspirin, ibuprofen, naproxen, celecoxib), cyclooxygenase-2 inhibitors, corticosteroids, and hyaluronic acid.

[0103] Methods for treating liver fibrosis may further comprise sequentially, separately, or simultaneously administering to the subject at least one additional therapy selected from among ACE inhibitors (e.g., benazepril, Lisinopril, Ramipril), a-Tocopherol, interferon-a, PPAR-antagonists, colchicine, corticosteroids, endothelin inhibitors, interleukin- 10, pentoxifylline, phosphatidylcholine, S-adenosyl-methionine, and TGF-pi inhibitors.

[0104] Methods for treating chronic kidney disease may further comprise sequentially, separately, or simultaneously administering to the subject at least one additional therapy selected from among ACE inhibitors (e.g., benazepril, Lisinopril, Ramipril), statins (e.g., Atorvastatin, Fluvastatin, Lovastatin, Pitavastatin, Pravastatin, Rosuvastatin calcium, Simvastatin), furosemide, erythropoietin, phosphate binders (e.g., calcium acetate, calcium carbonate), colecalciferol, ergocalciferol, and cyclophosphamide.EXAMPLESExample 1: Development of Nanoparticle Platform for Treating Senescent-associated Pathologies

[0105] This Example describes a nanoparticle platform allowing specific treatment of senescent cells and reduction of toxicities. Human tissue microarrays for lung fibrosis andliver fibrosis / cirrhosis were analyzed. P-selectin expression was significantly increased in human fibrotic lungs and human fibrotic / cirrhotic livers when compared to corresponding normal tissues (FIG. 6). The cell adhesion molecule P-selectin was induced in senescent tumor cells (FIGs. 1A-1BJ as well as in murine models of both liver and lung fibrosis (FIGs. 1C-1D). Interestingly, P-selectin is also found to be elevated in a range of senescence-linked human pathologies.

[0106] P-selectin-binding nanoparticles have been described in US Patent No.10,478,506, the contents of which are incorporated herein by reference. P-selectin-binding nanoparticles selectively deliver encapsulated agents to tumors. P-selectin-binding nanoparticles that encapsulate a fluorophore and either navitoclax or dBET6 were used. Both nanoparticles could visualize senescence and specifically deliver the drugs to senescent cells in vitro and in vivo (FIGs. 2A-2E, and 7A-7B)

[0107] Moreover, compared to similar doses of the toxic naked drugs navitoclax and dBET6, drug-loaded nanoparticles showed no notable toxicities (FIGs. 3A-3D) despite their high treatment efficacy in a model of murine liver (FIG. 4) and lung (FIG. 5) fibrosis. P- selectin+ senescent cells also accumulated in human lung fibrosis (FIG. 14A) and human liver fibrosis (FIG. 14B)

[0108] As a fibrotic tissue microenvironment promotes a pro-metastatic niche that favors metastasis seeding and growth, we tested whether clearing senescent cells in fibrotic tissues with navitoclax-encapsulated fucoidan-nanoparticles reshapes the microenvironment to prevent metastasis seeding and formation. We found that the clearance of senescent cells in fibrotic lungs reduces the seeding and metastatic burden of pancreatic ductal adenocarcinoma cells in the lung (FIGs. 8A-8C).

[0109] We identified an accumulation of P-selectin+ senescent cells in multiple tissues (heart, lung, liver, pancreas, and kidney) of wild-type aged mice when compared to young counterparts (FIGs. 9A-9B). In parallel, we observed that aged tissues (heart, lung, liver, pancreas, and kidney) are more fibrotic than young counterparts (FIGs. 9A-9B). In old wild-type animals, we visualized the accumulation of nanoparticles in the different organs (heart, lung, liver, pancreas, and kidney) where we observed p-selectin accumulation (FIGs.10A-10B)

[0110] Upon treatment of aged wild-type animals with either navitoclax -loaded or dBET6-loaded nanoparticles, we found a significant systemic reduction of fibrosis inmultiple aged organs (heart, lung, liver, pancreas, and kidney) (FIG. 11). In parallel, we evaluated that either navitoclax-loaded or dBET6-loaded nanoparticles restore the hepatic perfusion of fibrotic livers in old animals (FIGs. 12A-12C). Importantly, drug-loaded nanoparticles showed no notable toxicities when compared to similar doses of the toxic naked drugs navitoclax and dBET6, which induces thrombocytopenia and leucopenia (FIGs. 13A-13D)

[0111] FIGs. 15A-15C demonstrate that P-selectin knockdown decreases fucoidan nanoparticle uptake in senescent cells and inhibits FiNav-induced (navitoclax encapsulated in fucoidan nanoparticle) cell death in senescent cells.

[0112] FIGs. 16A-16D demonstrate xat FUCAl expression and enzymatic activity is upregulated in senescent cells. FUCA1 enzymatic activity is increased upon liver fibrosis and lung fibrosis (FIGs. 16E-16F). FIGs. 17A-17B demonstrate that Fucal knockdown decreases FUCA1 enzymatic activity in senescent cells. Fucal knockdown did not affect fucoidan nanoparticle uptake in senescent cells (FIG. 17C) but delayed FiNav-induced (navitoclax encapsulated in fucoidan nanoparticle) cell death in senescent cells. See FIG. 17D. P-selectin knockdown and Fucal knockdown reduced Fi-dBET6-induced (dBET6, a BRD4 PROTAC, encapsulated in fucoidan nanoparticle) BRD4 degradation in senescent cells (FIG. 18).

[0113] FIGs. 19A-19B demonstrates that FiNav and FidBET6 treatment changes the SASP profile in fibrotic lungs and fibrotic livers. 13 proteins are commonly downregulated between FiNav and FidBET6 treatment in both fibrotic lung and liver (FIG. 19C): Amphiregulin, angiopoietin-1, TNFSF13B, CCL2 / JE / MCP-1, CCL21 / 6Ckine, CCL3 / CCL4 / MIPl-aP, CCL5 / RANTES, chitinase 3-like 1, complement component C5 / C5a, IL1P / IL-1F2, MMP2, MMP9 and P-selectin / CD62P.

[0114] High fibrotic burden correlates with an increase of macrophages, exhausted CD8 T cells and a decrease in effective CD8 T cells in human fibrotic lungs (FIGs. 20A-20E). FiNav and Fi-dBET6 treatment reduces macrophages and increases CD8 T cells in fibrotic lungs. See FIG. 20F Thus, the nanoparticles of the present technology are useful for enhancing the efficacy of anti-cancer therapies that have difficulty penetrating the tumor such as immunotherapy, adoptive cell therapy and the like.

[0115] These results establish the utility for senolytic and senomorphic nanoparticles and provide support for their use in indications such as fibrosis. Accordingly, the polymericnanoparticle compositions of the present technology are useful in the methods for treating or ameliorating the effects of a senescence-associated pathology in a subject in need thereof. Nonlimiting examples of senescence-associated pathologies include lung fibrosis, atherosclerosis, Alzheimer’s disease, diabetes, liver fibrosis, chronic kidney disease, or osteoarthritis.EQUIVALENTS

[0116] The present technology is not to be limited in terms of the particular embodiments described in this application, which are intended as single illustrations of individual aspects of the present technology. Many modifications and variations of this present technology can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. Functionally equivalent methods and apparatuses within the scope of the present technology, in addition to those enumerated herein, will be apparent to those skilled in the art from the foregoing descriptions. Such modifications and variations are intended to fall within the scope of the present technology. It is to be understood that this present technology is not limited to particular methods, reagents, compounds compositions or biological systems, which can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.

[0117] In addition, where features or aspects of the disclosure are described in terms of Markush groups, those skilled in the art will recognize that the disclosure is also thereby described in terms of any individual member or subgroup of members of the Markush group.

[0118] As will be understood by one skilled in the art, for any and all purposes, particularly in terms of providing a written description, all ranges disclosed herein also encompass any and all possible subranges and combinations of subranges thereof. Any listed range can be easily recognized as sufficiently describing and enabling the same range being broken down into at least equal halves, thirds, quarters, fifths, tenths, etc. As a nonlimiting example, each range discussed herein can be readily broken down into a lower third, middle third and upper third, etc. As will also be understood by one skilled in the art all language such as “up to,” “at least,” “greater than,” “less than,” and the like, include the number recited and refer to ranges which can be subsequently broken down into subranges as discussed above. Finally, as will be understood by one skilled in the art, a range includeseach individual member. Thus, for example, a group having 1-3 cells refers to groups having 1, 2, or 3 cells. Similarly, a group having 1-5 cells refers to groups having 1, 2, 3, 4, or 5 cells, and so forth.

[0119] All patents, patent applications, provisional applications, and publications referred to or cited herein are incorporated by reference in their entirety, including all figures and tables, to the extent they are not inconsistent with the explicit teachings of this specification.

Claims

CLAIMS1. A method for treating a senescence-associated pathology in a subject in need thereof comprising administering to the subject an effective amount of a polymeric nanoparticle with affinity to P-selectin, wherein the nanoparticle comprises a non-covalent assembly of a. a sulfated polymer species comprising free hydroxyl moieties and free sulfate moieties capable of targeting P-selectin, the sulfated polymer species comprising one or more of a sulfated polysaccharide, a protein, or a fucoidan; and b. a senolytic or senom orphic drug; and optionally, a dye comprising a fluorophore; wherein the non-covalent assembly is a self-assembly of the sulfated polymer species around the senolytic or senomorphic drug; and wherein the subject exhibits an increased accumulation of senescent cells compared to a healthy control subject.

2. The method of claim 1, wherein the senescence-associated pathology is selected from the group consisting of atherosclerosis, Alzheimer’s disease, Parkinson’s disease, diabetic nephritis, diabetes, fibrotic diseases (e.g., lung fibrosis, liver fibrosis), metabolic dysfunction, stroke, chronic kidney disease, osteoarthritis, ischemic injury, sarcopenia, and organ decline after viral infection or cytotoxic cancer therapy.

3. A method for enhancing the efficacy of an anti-cancer therapy in a subject in need thereof comprising administering to the subject an effective amount of a polymeric nanoparticle with affinity to P-selectin, wherein the nanoparticle comprises a non-covalent assembly of a. a sulfated polymer species comprising free hydroxyl moieties and free sulfate moieties capable of targeting P-selectin, the sulfated polymer species comprising one or more of a sulfated polysaccharide, a protein, or a fucoidan; and b. a senolytic or senomorphic drug; and optionally, a dye comprising a fluorophore; wherein the non-covalent assembly is a self-assembly of the sulfated polymer species around the senolytic or senomorphic drtig; and wherein the subject comprises a tumor microenvironment including senescent cells, optionally wherein the anti-cancer therapy comprises immunotherapy (e.g., immune checkpoint blockade therapy), adoptive celltherapy, chemotherapy, or radiation therapy, optionally wherein the efficacy of the anticancer therapy is improved by eliminating fibrosis caused by the anti-cancer therapy.

4. The method of claim 3, wherein the polymeric nanoparticle is configured to selectively target senescent cells in the tumor microenvironment.

5. The method of claim 3 or 4, wherein the adoptive cell therapy comprises CAR T cell therapy or donor lymphocyte infusion.

6. The method of any one of claims 3-5, wherein the immunotherapy or adoptive cell therapy is administered intravenously, intratumorally, intraperitoneally, subcutaneously, intramuscularly, or intratumorally.

7. A method for preventing or mitigating metastasis in a subject in need thereof comprising administering to the subject an effective amount of a polymeric nanoparticle with affinity to P-selectin, wherein the nanoparticle comprises a non-covalent assembly of a. a sulfated polymer species comprising free hydroxyl moieties and free sulfate moi eties capable of targeting P-selectin, the sulfated polymer species comprising one or more of a sulfated polysaccharide, a protein, or a fucoidan; and b. a senolytic or senom orphic drug; and optionally, a dye comprising a fluorophore; wherein the non-covalent assembly is a self-assembly of the sulfated polymer species around the senolytic or senomorphic drug; and wherein the subject exhibits an increased accumulation of senescent cells compared to a healthy control subject.

8. The method of any one of claims 3-7, wherein the subject is diagnosed with or suffers from cancer.

9. The method of claim 8, wherein the cancer is breast cancer, endometrial cancer, ovarian cancer, colon cancer, lung cancer, stomach cancer, prostate cancer, renal cancer, pancreatic cancer, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), or acute myeloid leukemia (AML).

10. The method of claim 8 or 9, wherein the cancer is a relapsed or refractory cancer.11 . A method for improving tissue function or organ recovery in a subject in need thereof comprising administering to the subject an effective amount of a polymeric nanoparticle with affinity to P-selectin, wherein the nanoparticle comprises a non-covalent assembly ofa. a sulfated polymer species comprising free hydroxyl moieties and free sulfate moieties capable of targeting P-selectin, the sulfated polymer species comprising one or more of a sulfated polysaccharide, a protein, or a fucoidan; and b. a senolytic or senomorphic drug; and optionally, a dye comprising a fluorophore; wherein the non-covalent assembly is a self-assembly of the sulfated polymer species around the senolytic or senomorphic drug; and wherein the subject has received surgery' and exhibits an increased accumulation of senescent cells compared to a healthy control subject.

12. The method of claim 11, wherein the subject is an organ or tissue transplant recipient or arthroplasty recipient.

13. The method of any one of claims 1-12, wherein the senolytic or senomorphic drug is hydrophobic.

14. The method of any one of claims 1-13, wherein the senolytic drug comprises one or more of navitoclax, fisetin, dasatinib, quercetin, luteolin, curcumin, curcumin analog EF24, A1331852, Al 155463, geldanamycin, tanespimycin, alvespimycin, piperlongumine, FOXO4-related peptide, Nutlin3a, ouabain, proscillaridin A, digoxin or cardiac glycosides.

15. The method of any one of claims 1-13, wherein the senomorphic drug comprises one or more of BET-inhibitor PROTAC dBET6, CDK9 inhibitors (e.g., AZD-4573, KB-0742, Alvocidib Hydrochloride, AT-7519, FIT-039, GFH-009, QHRD107, enitociclib, fadraciclib, flavopiridol, dinaciclib, seliciclib, SNS-032, RGB-286638, NVP-2 etc.), rapamycin, resveratrol, kaempferol, apigenin, EGCG, metformin, ruxolitinib, cortisol, corticosterone, loperamide, nigul dipine, KU-60019, NBD peptide or Mmu-miR-2910-3p.

16. The method of any one of claims 1-15, wherein the polymeric nanoparticle has an intensity -weighted average diameter as determined by dynamic light scattering of about 20 nm and about 200 nm.

17. The method of any one of claims 1-16, wherein the sulfated polymer species comprises a fucoidan and optionally, dextran sulfate.

18. The method of any one of claims 1-17, wherein the polymeric nanoparticle is negatively charged.

19. The method of any one of claims 1-18, wherein the dye is a near infra-red dye.

20. The method of claim 19, wherein the near infra-red dye is selected from the group consisting of IR783, IR-5, IR-26, IR-1048, IR-1061, CF®700, CF®750, CF®770, CF®790, CF®700, CF®800, CF®820, CF®850, and CF®870.

21. The method of any one of claims 1-20, wherein the polymeric nanoparticle exhibits reduced off-target toxicity relative to the senolytic or senomorphic drug.

22. The method of claim 21, wherein the off-target toxicity comprises one or more of leukopenia, neutropenia, thrombocytopenia, dysgeusia, diarrhea, fatigue, nausea and anemia.

Citation Information

Patent Citations

  • Fucoidan nanogels and methods of their use and manufacture

    US20190142960A1

  • Treating liver disease by selectively eliminating senescent cells

    US20210169876A1

  • Senolytic car-t cells targeting UPAR, a cell surface and secreted senescence biomarker

    WO2020160518A1